- Czech RepublicVáclav HorejsíInstitute of Molecular Genetics AS CR
- FranceAndré PèlegrinInstitut de Recherche en Cancérologie de Montpellier, IRCM
- Armand BensussanHôpital Saint Louis
- ItalyFabio MalavasiUniversity of Torino Medical School
- NetherlandsRuurd TorensmaNijmegen Centre for Molecular Life Sciences
- SpainGiovanna RoncadorCentro Nacional de Investigaciones Oncológicas
- Leonor KremerCentro Nacional de Biotecnología/CSIC
- Núria PascualNb4D
- Pablo EngelMedical School, University of Barcelona
- United KingdomUniversity of OxfordLRF Haemato-oncology Group
- University of OxfordOxFabs
- University of OxfordLRF Lymphoma Antigens Group
What is EuroMAbNet?
Hybridoma technology for the production of monoclonal antibodies (mAb) represents one of the most important methodological advances in biomedicine. Monoclonal antibodies have become an indispensable tool for the study of human tissues and neoplasms. Antibody-based techniques such as immunohistochemistry and ELISA are important components of the diagnostic processes in routine hospital laboratories where they are invaluable in maximising diagnostic accuracy, and they are also used in extensively in research institutes and laboratories.
The availability of monoclonal antibodies has increased exponentially the potential for basic and applied biomedical research. Monoclonal antibodies permit a better understanding of pathways and interactions for the diagnosis, prevention and treatment of diseases.
EuroMAbNet is the first European network of laboratories specialised in the production and use of monoclonal antibodies. The objective of the Network is to allow people working in the field of monoclonal antibody production to exchange knowledge, share the most up-to-date technology and create common strategies to increase and standardise monoclonal antibody production.
In the EuroMAbNet web pages you will find detailed protocols for each step of monoclonal antibody production, along with our monoclonal antibody catalogue.
EuroMAbNet will design, develop and disseminate new technological information for monoclonal antibody production to the scientific community.